Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

Leukemia

Volumn 26, Issue 2, 2012, Pages 271-279

  Morrison, D J ^a   Hogan, L E ^a   Condos, G ^a   Bhatla, T ^a   Germino, N ^a   Moskowitz, N P ^a   Lee, L ^a   Bhojwani, D ^b   Horton, T M ^c   Belitskaya Levy, I ^a   Greenberger, L M ^d   Horak, I D ^d   Grupp, S A ^e   Teachey, D T ^e   Raetz, E A ^a   Carroll, W L ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Enzon Incorporated   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

acute lymphoblastic leukemia; EZN 3042; pediatric; survivin

Indexed keywords

ANTILEUKEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ASPARAGINASE; CASPASE 3; CELL PROTEIN; CYCLIN B1; DOXORUBICIN; ETOPOSIDE; EZN 3042; MESSENGER RNA; METHOTREXATE; PREDNISOLONE; SHORT HAIRPIN RNA; SURVIVIN; SURVIVIN 2ALPHA; SURVIVIN 2B; TEMSIROLIMUS; TOP2A PROTEIN; TRIPTOLIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; APOPTOSIS; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; LEUKEMIA RELAPSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA PRIMERS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84856716236     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.199     Document Type: Review

References (45)

1. Bhojwani D, Kang H, Moskowitz NP, Min DJ, Lee H, Potter JW et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2006; 108: 711-717. (Pubitemid 44061374)
2. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F et al. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007; 6: 1502-1509.
3. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28: 1133-1139. (Pubitemid 47062670)
4. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087-1098. (Pubitemid 43881300)
5. Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C et al. Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 2007; 211: 532-540. (Pubitemid 46502429)
6. Fortugno P, Beltrami E, Plescia J, Fontana J, Pradhan D, Marchisio PC et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100: 13791-13796. (Pubitemid 37499145)
7. Hattori M, Sakamoto H, Satoh K, Yamamoto T. DNA demethylase is expressed in ovarian cancers and the expression correlates with demethylation of CpG sites in the promoter region of c-erbB-2 and survivin genes. Cancer Lett 2001; 169: 155-164. (Pubitemid 32595563)
8. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000; 19: 617-623. (Pubitemid 30102912)
9. Capalbo G, Rodel C, Stauber RH, Knauer SK, Bache M, Kappler M et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007; 183: 593-599. (Pubitemid 350124276)
10. Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F et al. Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol 2007; 82: 193-198. (Pubitemid 46431865)
11. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene 2007; 26: 2678-2684. (Pubitemid 46663841)
12. Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 2004; 279: 15196-15203. (Pubitemid 38618915)
13. Tirro E, Consoli ML, Massimino M, Manzella L, Frasca F, Sciacca L et al. Altered expression of c-IAP1, survivin, and Smac contributes to chemotherapy resistance in thyroid cancer cells. Cancer Res 2006; 66: 4263-4272.
14. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002; 303: 124-131.
15. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-1925. (Pubitemid 30661078)
16. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007; 13 (15 Part 1): 4407-4414. (Pubitemid 47219707)
17. Fangusaro JR, Caldas H, Jiang Y, Altura RA. Survivin: an inhibitor of apoptosis in pediatric cancer. Pediatr Blood Cancer 2006; 47: 4-13. (Pubitemid 43787902)
18. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
19. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285: 324-328. (Pubitemid 32095036)
20. Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S et al. Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int 2005; 55: 324-330. (Pubitemid 40910665)
21. Carter BZ, Andreeff M. Targeting survivin in leukemia. Oncol Rev 2008; 1: 195-204.
22. Hansen JB, Fisker N, Westergaard M, Kjaerulff LS, Hansen HF, Thrue CA et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther 2008; 7: 2736-2745.
23. Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Hog A et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 2010; 38: e3.
24. Min DJ, Moskowitz NP, Brownstein C, Lee H, Horton TM, Carroll WL. Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. Apoptosis 2006; 11: 1977-1986. (Pubitemid 44691581)
25. Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, Fish J et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 2008; 112: 2020-2023.
26. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z et al. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006; 108: 630-637. (Pubitemid 44061364)
27. Hogan L, Bhojwani D, Wang J, Morrison D, Yang J, Zhang Y et al. Upregulation of genes involved in folate metabolism characterize late but not early relapse in childhood acute lymphoblastic leukemia. Blood [abstract] 2009; 114: 689.
28. Sapra P, Wang M, Bandaru R, Zhao H, Greenberger LM, Horak ID. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucl Acids 2010; 29: 97-112.
29. Hu H, Shikama Y, Matsuoka I, Kimura J. Terminally differentiated neutrophils predominantly express Survivin-2 alpha, a dominantnegative isoform of survivin. J Leukoc Biol 2008; 83: 393-400. (Pubitemid 351225620)
30. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
31. Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A et al. A functional Notch-survivin gene signature in basal breast cancer. Breast Cancer Res 2008; 10: R97.
32. Wang RH, Zheng Y, Kim HS, Xu X, Cao L, Luhasen T et al. Interplay among BRCA1, SIRT1, and survivin during BRCA1-associated tumorigenesis. Mol Cell 2008; 32: 11-20.
33. Hayashi N, Asano K, Suzuki H, Yamamoto T, Tanigawa N, Egawa S et al. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate 2005; 65: 10-19. (Pubitemid 41318826)
34. Li QX, Zhao J, Liu JY, Jia LT, Huang HY, Xu YM et al. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther 2006; 5: 860-866. (Pubitemid 44775148)
35. Nakao K, Hamasaki K, Ichikawa T, Arima K, Eguchi K, Ishii N. Survivin downregulation by siRNA sensitizes human hepatoma cells to TRAIL-induced apoptosis. Oncol Rep 2006; 16: 389-392.
36. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60: 2805-2809. (Pubitemid 30395796)
37. Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006; 118: 812-820. (Pubitemid 43157656)
38. Kim R, Emi M, Matsuura K, Tanabe K. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther 2007; 14: 1-11. (Pubitemid 44952228)
39. Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boue DR et al. Survivin, survivin-2B, and survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. Br J Cancer 2005; 92: 359-365. (Pubitemid 40343153)
40. Takamizawa S, Scott D, Wen J, Grundy P, Bishop W, Kimura K et al. The survivin: fas ratio in pediatric renal tumors. J Pediatr Surg 2001; 36: 37-42. (Pubitemid 32044312)
41. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res 2004; 10: 3737-3744. (Pubitemid 38697607)
42. Zhu N, Gu L, Li F, Zhou M. Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells. Mol Cancer Ther 2008; 7: 1101-1109.
43. Talbot D, Davies J, Callies S, Andre V, Lahn M, Ang J et al. First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. J Clin Oncol 2008; 26: 3518.
44. Tolcher AW, Patnaik A, Papadopoulos KP, Agnew J, Lokiec FM, Rezai K et al. Results of a phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with or without docetaxel in adult patients with advanced solid tumors or lymphoma. Proceedings of the 102nd Annual Meeting of AACR, 2011 LB-409 (abstract).
45. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26: 5198-5203.